Clinical Validation of the Withings ECG Monitor for the Detection of Atrial Fibrillation

Atrial Fibrillation Clinical Trial

— QDA-UE  

Official title:

Clinical Validation of the Withings ECG Monitor for the Detection of Atrial Fibrillation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05266235
• Other study ID #: 2021-A02730-41
• Status: Completed
• Phase: N/A
• Start date: April 14, 2022
• Est. completion date: July 28, 2022

Study information

• Verified date: March 2023
• Source: Withings
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to demonstrate the performance of Withings WBS08 in the automatic identification of atrial fibrillation and sinus rhythm.

Description:

Patients included will be those presenting for consultation in the various participating clinical services. For each patient, an ECG will be recorded with the WBS08 and with the reference device Cardiovit FT1, at rest and after an exercise session.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 274
• Est. completion date: July 28, 2022
• Est. primary completion date: July 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female who are 18 years of age or older
• Subject able to read, understand and provide written informed consent
• Subject willing and able to participate in the study procedures as described in the consent form
• Subject able to communicate effectively with and willing to follow instructions from the study staff
• Subject affiliated to a social security system For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening. Subjects may have any type of AF including paroxysmal, persistent, and permanent AF.

Exclusion Criteria:

• Vulnerable subject with regard to regulations in force :
• Subject who is deprived of liberty by judicial, medical or administrative decision,
• Underage subject,
• Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form
• Subject within several of the above categories
• Subject who refused to participate in the study
• Subject mentally impaired resulting in limited ability to cooperate
• Subject with a pacemaker, ICD (Implantable cardioverter defibrillator) or other implanted electronic stimulator
• Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being ablle to hold still (e.g Parkinson disease)
• Patient unable to stay in an upright position for the duration of study measures
• Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the investigator, may increase the risk to the subject or renders data uninterpretable (e.g. recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)
• Acute pulmonary embolism or pulmonary infarction, within 90 days of screening
• Stroke or transient ischemic attack within 90 days of screening
• Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3rd degree heart block).
• History of abnormal life-threatening rhythms as determined by the investigator (e.g., ventricular tachycardia, ventricular fibrillation, 3rd degree heart block)
• Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis over electrode attachment sites
• Known sensitivity to medical adhesives, isopropyl alcohol, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands
• Weight more than 180 kg

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Device:
• Validation of the Withings bodyscan scale WBS08
Participants will undergo simultaneous recordings of ECGs with the comparator and the study device

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires de Bruxelles - Hôpital Erasme	Brussel
France	Henri Mondor University Hospital	Créteil	Val De Marne
France	George Pompidou European Hospital	Paris
France	Poitiers University Hospital	Poitiers	Vienne

Sponsors (1)

Lead Sponsor	Collaborator
Withings

Countries where clinical trial is conducted

Belgium,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance in the identification of atrial fibrillation and sinus rhythm	The co-primary endpoints are the sensitivity and specificity in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.	10 months
Secondary	Evaluation of the classification into heart rate subgroups	The classification into heart rate subgroups will be evaluated for the pairs of strips such that the rhythm classification of the 12-lead ECG is either SR or AF and such that the strip generated by the SUT is classified as either SR or AF and such that the strip generated by the SUT is classified as either SR or AF. The evaluation will be assessed with the concordance of classifications, i.e. the percentage P of identical classifications by the SUT and the reference method, into each of the four following subgroups : SR with a HR between 50 and 99 bpm; SR with a HR between 100 and 150 bpm; AF with a HR between 50 and 99 bpm; AF with a HR between 100 and 150 bpm	10 months
Secondary	Assessment of the clinical equivalence of ECG waveforms	Clinical equivalence of ECG waveforms will be qualitatively and quantitatively assessed between the 6-leads generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG by a board of certified cardiologists : The visibility and polarity of the P waves, QRS complexes and T waves will be determined by cardiologists and according to a set of predetermined rules.	10 months
Secondary	Assessment of the clinical equivalence of ECG waveforms	The durations of the QT intervals, QRS complex widths, and PR intervals will be measured by cardiologists with a caliper on the first beat of the 6 marked PQRST complexes and according to a set of predetermined rules for each of the 6 leads of the strips generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG.	10 months
Secondary	Determination of the heart rate	The heart rate will be determined by independent cardiologists, or cardiac technicians supervised by cardiologists, from each six-channel strip recorded with the SUT and from each lead I, II, III, aVR, aVL, aVF of the 12-lead strip of the reference ECG. For each simultaneous pair of strips, a reviewer will independently select a common lead with the best signal quality. Then, the reviewer will determine one or several window(s) on the selected lead according to a set of predetermined rules. Finally the number N of complete RR intervals inside these windows and the duration Dt (< 30s) of the windows will be measured with a caliper. The heart rate will then be calculated as 60*N/Dt. The reader-estimated heart rates will later be compared to the heart rates calculated by the SUT	10 months